LINCOLN PHARMA LTD
LINCOLN · General/Diversified · NSE
₹604
Current Market Price
Fair Value (DCF)
₹964
Margin of Safety
+59.5%
Updated 2d ago
YieldIQ Score
70/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
60%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹1,210 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
16.1%
Return on capital employed
EV / EBITDA
9.8×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
111.1×
EBIT covers interest
Current Ratio
4.71×
Short-term liquidity
Asset Turnover
0.78×
Revenue per ₹ of assets
Revenue CAGR (3Y)
10.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹604
Bear case
₹524.05
MoS -15.3%
Base case
₹963.54
MoS +37.3%
Bull case
₹1,094.71
MoS +44.8%
Ratio Trends
LINCOLN · last 8 annual periods
ROE
12.3%
ROCE
18.5%
Operating Margin
—
Debt / Equity
0.00×
PE
54.1×
EV / EBITDA
6.1×
Historical Financials
LINCOLN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹413 Cr | ₹472 Cr | ₹112 Cr | ₹142 Cr | ₹623 Cr | +10.8% |
| EBITDA | — | ₹105 Cr | ₹111 Cr | ₹134 Cr | ₹124 Cr | +4.3% |
| EBIT | ₹82.5 Cr | ₹97.4 Cr | ₹18.1 Cr | ₹22.7 Cr | — | -27.6% |
| PAT | ₹60.4 Cr | ₹69.4 Cr | ₹12.6 Cr | ₹18.6 Cr | ₹82.3 Cr | +8.1% |
| EPS (diluted) | ₹30.20 | ₹34.63 | ₹6.27 | ₹9.28 | — | -25.5% |
| CFO | ₹71.4 Cr | ₹76.2 Cr | ₹39.3 Cr | ₹63.2 Cr | ₹93.0 Cr | +6.8% |
| CapEx | — | — | — | — | ₹-19.2 Cr | — |
| FCF | — | — | — | — | ₹73.8 Cr | +0.0% |
| Total Assets | — | ₹534 Cr | ₹587 Cr | ₹700 Cr | ₹797 Cr | +10.5% |
| Total Debt | — | — | ₹2.0 Cr | ₹1.1 Cr | — | -14.5% |
| Shareholders' Equity | — | — | ₹502 Cr | ₹593 Cr | ₹672 Cr | +7.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
LINCOLN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| BAJAJHCARE BAJAJHCARE | — | — | Pending | 8.5% | — |
| INDSWFTLAB INDSWFTLAB | — | — | Pending | 21.4% | — |
| JAGSNPHARM JAGSNPHARM | — | — | Pending | 23.1% | — |
| SAKAR SAKAR | — | — | Pending | 6.1% | — |
| SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for LINCOLN in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. LINCOLN PHARMA LTD (LINCOLN.NS) trades at 604.00 vs a model fair value of 963.54, a gap of 59.5%. Piotroski F-score: 6/9. Moat label: Wid...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of LINCOLN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for LINCOLN →
Compare
Head-to-head with peers
Compare LINCOLN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse LINCOLNNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.